Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Clover Health Investments, Corp. reported that CEO Andrew Toy will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2026, with a live webcast available through the company’s investor relations website. The slide deck for this event is furnished as an exhibit.
The company also issued a press release on January 14, 2026 announcing preliminary Medicare Advantage Annual Election Period results, which is likewise furnished as an exhibit. The accompanying materials include forward-looking statements discussing expected 2026 GAAP net income profitability, the impact of a 4.0 Stars rating for Clover’s PPO Medicare Advantage plans for payment year 2026, its 2026 financial outlook, membership growth and retention, Clover Assistant usage and investment, CMS’ 2026 rate update, Part D direct subsidies, and cost efficiency initiatives, all subject to significant risks and uncertainties.
Clover Health Investments director and 10% owner Vivek Garipalli reported a large RSU vesting and related share movements. On January 7, 2026, the final 20% of a restricted stock unit grant from January 7, 2021 vested. This delivered 1,686,750 shares of Class B common stock and triggered the automatic conversion of 1,655,949 Class B shares into the same number of Class A shares, which were withheld by the company to satisfy tax obligations at a value of $2.59 per share.
Following these transactions, Garipalli directly held 1,856,247 shares of Class A common stock and 8,591,093 shares of Class B common stock75,694,143 shares of Class B common stock through NJ Healthcare Investments, LLC and 11,500,000 shares of Class B common stock through Caesar Clover, LLC, with each Class B share convertible into one Class A share.
Clover Health Investments, Corp. reported that director Demetrios L. Kouzoukas received an equity award in the form of restricted stock units. On January 6, 2026, he acquired 79,365 shares of Class A common stock at a price of $0 per share, reflecting the grant of time-based RSUs rather than a cash purchase.
These RSUs represent shares that will vest in full on the first anniversary of January 6, 2026, as long as he continues to serve as a director through that vesting date. After this grant, Kouzoukas beneficially owned 605,980 shares of Class A common stock, held directly.
Clover Health Investments, Corp. director reports stock-based award. Director Carladenise Armbrister Edwards received 79,365 shares of Class A Common Stock on January 6, 2026, as part of a time-based restricted stock unit (RSU) grant at a price of $0 per share. These RSUs represent stock that will vest in full on the first anniversary of January 6, 2026, if she continues serving as a director through that date. Following this grant, she beneficially owns 352,592 shares of Class A Common Stock in total, reported as directly held.
Clover Health Investments director Anna U. Loengard reported an equity grant and updated share holdings. On January 6, 2026, she acquired 79,365 shares of Class A Common Stock at $0, representing time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, if she continues to serve as a director through that date. Following this award, she beneficially owns 527,456 Class A shares directly. She also reports indirect beneficial ownership of 27,600 Class A shares held in a custodial IRA for her son and 29,610 Class A shares held in a custodial IRA for her daughter, for which she serves as custodian.
Clover Health Investments, Corp. director William G. Robinson Jr reported an equity award of 79,365 shares of Class A common stock on January 6, 2026. These shares represent time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, as long as he continues to serve as a director through that date. The award was recorded at a price of $0 per share, reflecting a grant rather than an open-market purchase. After this grant, Robinson beneficially owned a total of 597,987 shares of Class A common stock in direct ownership.
Clover Health Investments, Corp. director Thomas L. Tran reported an equity award of Class A Common Stock. On January 6, 2026, he was granted 79,365 shares of Class A Common Stock, received as time-based restricted stock units (RSUs) at a price of $0 per share, meaning this was a compensatory grant rather than an open-market purchase.
According to the filing, these RSUs represent shares that will vest in full on the first anniversary of January 6, 2026, as long as Tran continues to serve as a director through that vesting date. After this award, Tran beneficially owns 180,029 shares of Class A Common Stock directly. This filing reflects routine director compensation in the form of equity.
Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO for Medicare Advantage, reported a small insider sale of Class A common stock. On January 7, 2026, Reynoso sold 2,102 shares at a weighted average price of $2.53 per share in an open-market transaction. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025, which automates trades according to preset instructions. After this transaction, Reynoso directly beneficially owned 2,757,029 shares of Clover Health Class A common stock.
An insider of CLOV has filed a Form 144 indicating an intent to sell 2,102 shares of common stock through broker Morgan Stanley Smith Barney LLC on or about January 7, 2026 on the NASDAQ. These shares were acquired on January 3, 2026 as restricted stock units from the issuer. The filing notes that 424,304,898 common shares were outstanding. Over the prior three months, the same seller completed additional common stock sales labeled as “10b5-1 Sales”.
Clover Health Investments, Corp. insider Jamie L. Reynoso, who serves as CEO, Medicare Advantage, reported a small open-market sale of company stock. On 12/18/2025, Reynoso sold 4,913 shares of Class A common stock at a weighted average price of $2.61 per share, with individual trade prices ranging from $2.58 to $2.64. The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on March 13, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Reynoso beneficially owns 2,767,240 shares of Class A common stock, held in direct form.